Analyzing Atossa Genetics (ATOS) and Its Competitors

Atossa Genetics (NASDAQ: ATOS) is one of 121 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it weigh in compared to its competitors? We will compare Atossa Genetics to similar businesses based on the strength of its risk, valuation, dividends, profitability, analyst recommendations, institutional ownership and earnings.

Valuation & Earnings

This table compares Atossa Genetics and its competitors gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Atossa Genetics N/A -$11.40 million -0.46
Atossa Genetics Competitors $1.48 billion $146.48 million 39.08

Atossa Genetics’ competitors have higher revenue and earnings than Atossa Genetics. Atossa Genetics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Atossa Genetics has a beta of 3.82, meaning that its share price is 282% more volatile than the S&P 500. Comparatively, Atossa Genetics’ competitors have a beta of 1.12, meaning that their average share price is 12% more volatile than the S&P 500.

Profitability

This table compares Atossa Genetics and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Atossa Genetics N/A -172.50% -94.42%
Atossa Genetics Competitors -30.00% -41.48% -13.59%

Analyst Recommendations

This is a breakdown of recent recommendations for Atossa Genetics and its competitors, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Atossa Genetics 0 0 2 0 3.00
Atossa Genetics Competitors 814 2815 4988 252 2.53

Atossa Genetics currently has a consensus price target of $9.50, suggesting a potential upside of 274.02%. As a group, “Surgical & medical instruments” companies have a potential upside of 28.98%. Given Atossa Genetics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Atossa Genetics is more favorable than its competitors.

Insider & Institutional Ownership

8.6% of Atossa Genetics shares are held by institutional investors. Comparatively, 50.8% of shares of all “Surgical & medical instruments” companies are held by institutional investors. 3.3% of Atossa Genetics shares are held by insiders. Comparatively, 15.9% of shares of all “Surgical & medical instruments” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Atossa Genetics competitors beat Atossa Genetics on 7 of the 12 factors compared.

Atossa Genetics Company Profile

Atossa Genetics Inc. a clinical-stage pharmaceutical company, focuses on the development and sale of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions in the United States. The company is conducting a Phase 2 clinical study using microcatheters to deliver fulvestrant as a potential treatment of ductal carcinoma in situ and breast cancer; and a pharmaceutical program under development is Endoxifen, an active metabolite of tamoxifen, as well as treatment for breast density and other breast health conditions. It offers ForeCYTE Breast Aspirator and FullCYTE Breast Aspirator, which collects specimens of nipple aspirate fluid (NAF)for cytological testing at a laboratory; and a transport kit to assist with the packaging and transport of NAF samples to a laboratory, as well as manufactures and sells various medical devices primarily consisting of tools to assist breast surgeons. Atossa Genetics Inc. was founded in 2009 and is headquartered in Seattle, Washington.

Receive News & Ratings for Atossa Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atossa Genetics and related companies with MarketBeat.com's FREE daily email newsletter.